CAR T-cell therapy represents a groundbreaking advancement in the field of oncology, particularly in the treatment of certain types of blood cancers such as leukemia and lymphoma. This innovative ...

At Fred Hutch Cancer Center and University of Washington Medical Center, we have an experienced team that provides CRS-HIPEC. Many of our patients receive all their cancer care through Fred Hutch and ...

Among patients with heavily pretreated chronic lymphocytic leukemia, treatment with Epkinly monotherapy showed deep responses ...

Weighing the Risk of Infection Versus the Benefits of Social Interactions in Our Pediatric Oncology Patients The three-center Mayo Clinic experience with ... No patients received prophylactic ...

Of the 57 patients, 18 (31.6%) developed cytokine release syndrome (CRS) and two had immune effector cell–associated neurotoxicity syndrome (ICANS). All CRS and ICANS resolved, and all patients ...

The study showed that all doses of POLB 001 significantly reduced clinically observed Cytokine Release Syndrome (CRS) scores, reinforcing its potential in preventing and treating cancer ...